Earns revenue by licensing self-discovered immuno-oncology antibody programs and targets to pharmaceutical partners for upfront, milestone and royalty payments, and by running partner-funded early-phase clinical development of a licensed program.
Geographic Exposure
United Kingdom89.33%
United States10.67%
Revenue Drivers
Immuno-oncology antibody out-licensing
Licensing discovered antibody programs to pharmaceutical partners for upfronts, milestones and royalties
CORE89.3%
Partner-funded early-phase clinical development
Conducting early-phase trials for a licensed antibody program on a partner's behalf
SIGNIFICANT10.7%
End Markets
AstraZeneca
Gilead Sciences
Pharmaceutical and biotechnology licensees
Specializations
Unigen AI/ML computational discovery platformImmune checkpoint target discoveryBispecific and multispecific antibody enablementDual and triple checkpoint blockade combinationsOvarian cancer maintenance therapy trialsRoyalty interest monetisation+1 more
